产品说明书

Atractyloside A

Print
Chemical Structure| 126054-77-1 同义名 : 白术甙A
CAS号 : 126054-77-1
货号 : A132263
分子式 : C21H36O10
纯度 : 99%+
分子量 : 448.505
MDL号 : MFCD16621069
存储条件：

粉末 Sealed in dry,2-8°C

液体 -20°C:3-6个月-80°C:12个月
溶解度 :

DMSO: 50 mg/mL(111.48 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO
动物实验配方：

IP 5% DMSO + 30% PEG400 +2% tween80 + 63% water 1 mg/mL clear

生物活性
描述 Atractyloside A is a natural TCM reference compound. The atractyloside might be potentially targets CAFs (cancer-associated fibroblasts) and inhibits the development as well as metastasis of CC(colon cancer) by changing the TM E(tumor microenvironment)[1]. ATR (Atractyloside) treatment blocks ANT2 (Adenine nucleotide translocase 2) expression, promotes the activation of AMPK, then decreases the mTOR activity, and finally promotes autophagosomes formation, thus accelerating the degradation of HFD(high-fat diet)-induced accumulated lipids in the liver[2]. Treatment with AA increased MTL, GAS, ZO-1, and OCLN levels, while reducing AQP1, AQP3, and FGF2 levels. In addition, phosphorylation of p38 and myosin light-chain kinase (MLCK) expression were inhibited. AA (Atractyloside A) improved gastrointestinal function by protecting the intestinal mucosal barrier via inhibition of the p38 MAPK pathway[3]. Low concentrations (2.5, 5, and 7.5 μM) of ATR treatment could activate autophagy to accelerate the degradation of TGs in steatosis HepG2 cells; the mechanism may be related to the activation of the AMPK/mTOR pathway induced by the increased ADP/ATP ratio. In addition, the ideal concentration of ATR for improving steatotic HepG2 cells was 7.5 μM[4].
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

2.23mL

0.45mL

0.22mL

11.15mL

2.23mL

1.11mL

22.30mL

4.46mL

2.23mL
参考文献

[1]Qi L, Song F, Han Y, Zhang Y, Ding Y. Atractyloside targets cancer-associated fibroblasts and inhibits the metastasis of colon cancer. Ann Transl Med. 2020 Nov;8(21):1443

[2]Zhang P, Cheng X, Sun H, Li Y, Mei W, Zeng C. Atractyloside Protect Mice Against Liver Steatosis by Activation of Autophagy via ANT-AMPK-mTORC1 Signaling Pathway. Front Pharmacol. 2021 Sep 21;12:736655

[3]Tu J, Xie Y, Xu K, Qu L, Lin X, Ke C, Yang D, Cao G, Zhou Z, Liu Y. Treatment of Spleen-Deficiency Syndrome With Atractyloside A From Bran-Processed Atractylodes lancea by Protection of the Intestinal Mucosal Barrier. Front Pharmacol. 2020 Nov 20;11:583160

[4]Zhang P, Li L, Sun H, Zhang Y, Zhang G, Zhang T, Zeng C. Mitochondrial Energy-Regulating Effect of Atractyloside Inhibits Hepatocellular Steatosis Through the Activation of Autophagy. Front Pharmacol. 2020 Sep 30;11:575695